Skip to content

Emergent Biosolutions EBS Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin54.2%+19.0pp56.1%+21.4pp54.5%+21.0pp53.5%+26.3pp35.2%-6.0pp
Efficiency
Asset turnover0.5×-0.1×0.5×-0.1×0.5×-0.1×0.6×0.0×0.6×+0.1×
Liquidity
Current ratio4.3×-2.0×+1.3×5.8×+2.9×5.7×+4.6×6.3×+5.2×
Leverage
Debt-to-equity1.1×-0.1×1.1×-0.3×1.2×-0.2×1.3×-1.0×1.2×-0.2×
Per Share
Book value per share$9.26-4.0%$9.22+1.2%$10.31+12.7%$9.89+34.7%$9.65-24.2%
Valuation
Market capitalization$411.74M+22.0%$649.15M+25.3%$470.56M+6.5%$367.46M+2.8%$264.08M+99.9%
Price / sales0.6×+0.3×0.9×+0.4×0.6×+0.2×0.4×+0.1×0.3×+0.2×
Price / book0.8×+0.2×1.2×+0.2×0.8×-0.1×0.7×-0.2×0.5×+0.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Emergent Biosolutions's profit margins?
Emergent Biosolutions (EBS) runs a 54.2% gross margin and a 15.0% operating margin, with a 9.6% net margin.
Where do Emergent Biosolutions's ratios come from?
Every ratio is computed from Emergent Biosolutions's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.